Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02689219
Recruitment Status : Active, not recruiting
First Posted : February 23, 2016
Last Update Posted : April 2, 2019
Sponsor:
Information provided by (Responsible Party):
Costantine Albany, Indiana University School of Medicine

Brief Summary:
This is a Phase II study to evaluate the activity of brentuximab vedotin in relapsed/refractory non-seminomatous germ cell tumors (NSGCT).

Condition or disease Intervention/treatment Phase
Germ Cell Tumors Testis Cancer Testicular Cancer Embryonal Carcinoma Nonseminomatous Germ Cell Tumor Drug: Brentuximab Vedotin Phase 2

Detailed Description:

Primary Objective To determine the anti-tumor efficacy of brentuximab vedotin in relapsed/ refractory NSGCT.

Secondary Objectives

  1. To determine the progression free survival in patients with relapsed/ refractory NSGCT treated with brentuximab vedotin.
  2. To determine the overall survival of patients with relapsed/ refractory NSGCT treated with brentuximab vedotin.
  3. To determine the safety and tolerability of brentuximab vedotin in this patient population.

Eligible patients will be divided into two cohorts, those who are CD30 positive and those who are CD30 negative/unknown. Both groups will be treated similarly and in parallel but analyzed separately. CD30 status may be unknown in the unlikely case of tumor-marker-only relapse or when a fresh tumor biopsy is not feasible, and archival tumor tissue is not obtainable despite efforts to do so. These patients will be included in the CD30 negative cohort for analysis purposes, since statistically NSGCT are more likely to be CD30 negative. The number of such patients with unknown CD30 status should not exceed 5 patients.

Eligible patients will be treated with brentuximab vedotin at 1.8 mg/kg IV every 3 weeks (maximum dose of 180 mg) indefinitely until disease progression, unacceptable toxicity, or study closure.Eligible patients with grade 2 peripheral neuropathy at enrollment will be treated with brentuximab vedotin at 1.2 mg/kg IV every 3 weeks (maximum dose of 180 mg) indefinitely until disease progression, unacceptable toxicity, or study closure. Response to treatment will be assessed clinically with history, physical exam and tumor markers measurement (BHCG and AFP) on day 1 of each cycle and with CT scans after cycle 2, 4, and every 4 cycles thereafter while receiving treatment.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 58 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Actual Study Start Date : March 9, 2016
Actual Primary Completion Date : November 13, 2018
Estimated Study Completion Date : December 31, 2019


Arm Intervention/treatment
Experimental: CD30 positive
Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
Drug: Brentuximab Vedotin
Both cohorts will be treated similarly and in parallel but analyzed separately.
Other Name: SGN-35

Experimental: CD30 negative/unknown
Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
Drug: Brentuximab Vedotin
Both cohorts will be treated similarly and in parallel but analyzed separately.
Other Name: SGN-35




Primary Outcome Measures :
  1. Objective response (proportion of patients who achieve either a partial or complete response) [ Time Frame: Before cycle 3 (i.e., at +43 days) ]
    Measured by CT and MRI for target lesions, serum markers AFP or beta-hCG, in patients whose only evidence of disease is serum tumor markers


Secondary Outcome Measures :
  1. Progression free survival [ Time Frame: From date of initiation of therapy until the time of disease progression or death (which ever comes first) up to 2 years ]
  2. Toxicity [ Time Frame: Every cycle (i.e. at +22 days, +43 days, etc.) ]
    Toxicities will be assessed based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The maximum grade of each toxicity will be recorded for each patient over the course of treatment (all cycles).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Subject must meet all of the following applicable inclusion criteria to participate in this study:

  1. Age ≥ 18 years at the time of informed consent.
  2. Patients with histologically or serologically confirmed relapsed/refractory non-seminoma germ cell tumor, (i.e., embryonal carcinoma, choriocarcinoma, or yolk sac tumors) including female GCT and primary mediastinal NSGCT.
  3. Patients must have progressed after prior high dose chemotherapy (HDCT) treatment, been deemed not to be a candidate for high dose chemotherapy or refused high-dose chemotherapy, and be considered incurable by other standard therapies including further chemotherapy or surgery. There is no maximum allowable number of previous therapies.

    "Failure" of prior therapy is defined as:

    1. A >25% increase in the products of perpendicular diameters of measurable tumor masses during prior therapy which are not amenable to surgical resection.
    2. The presence of new tumors which are not amenable to surgical resection.
    3. An increase in AFP or beta-hCG (two separate determinations at least one week apart are required if rising tumor markers are the only evidence of failure).

    NOTE: Patients with clinically growing "teratoma" (normal declining tumor markers and radiographic or clinical progression) should be considered for surgery.

  4. Patients must have evidence of recurrent or metastatic carcinoma by one or more of the following:

    i) The appearance of metastatic disease by standard imaging techniques ii) The appearance of rising serum tumor marker, AFP or beta-hCG NOTE: If a rising tumor marker is the only evidence of progressive disease, at least 2 consecutive rising values at least one week apart are needed. Patients with only evidence of disease is rising tumor marker AFP and beta-hCG will be provided alternate causes of increased serum levels of these markers are not present, such as cross reaction with luteinizing Hormone (LH) (that can be tested if needed by testosterone suppression of LH), hepatitis, use of marijuana or second primary tumor, etc.

  5. Patients with primary medistinal non seminomatous germ cell tumor are eligible if they have received first line platinum based chemotherapy and their recurrence is not amenable to surgical resection based on the treating physician expert opinion.
  6. Patients with late relapse (>2 years) of non seminomatous germ cell tumors are eligible if they have received first line platinum based chemotherapy and their recurrence is not amenable to surgical resection based on the treating physician expert opinion.
  7. Patients with brain metastases are allowed onto the study as long as patients have completed their treatment for brain metastasis, no longer require corticosteroids, and are asymptomatic. Subjects with neurological symptoms should undergo a head CT scan or brain MRI to exclude brain metastasis, at the discretion of the treating physician.
  8. Patients with ECOG performance status of 0-2.
  9. Adequate organ and marrow function as defined below:

    1. Hemoglobin ≥ 8 g/dL
    2. Absolute neutrophil count ≥ 1,000/mm3
    3. Platelet count ≥ 75,000/mm3
    4. Total bilirubin ≤ 1.5 × ULN except patients with documented Gilbert's syndrome (≤ 3 × ULN)
    5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; for patients with hepatic metastases, ALT and AST ≤ 5 × ULN
    6. Calculated creatinine clearance ≥ 30 mL/min as determined by the Cockcroft-Gault equation.
  10. Patients who are willing and able to comply with the protocol and study procedures including willingness to undergo tumor biopsy for tumor cells before therapy to assess for CD30 status (unless archival tumor tissue from orchiectomy or other previous sample is not obtainable despite efforts to do so and a fresh tumor biopsy is not feasible).
  11. Females of childbearing potential must not be pregnant or breast-feeding. Male and female patients of reproductive potential must agree to use two forms of highly effective contraception from the screening visit through 28 days after the last dose of study drug. Acceptable forms of effective contraception include:

    • Oral, injected or implanted hormonal methods of contraception.
    • Placement of an intrauterine device (IUD) or intrauterine system (IUS).
    • Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
    • Male sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate).
    • True abstinence: When this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.] Pregnancy tests for females of childbearing potential are required; must be serum at screening and the post treatment safety assessment visit. A positive urine pregnancy test must be confirmed by a serum pregnancy test and a pelvic US since some NSGCT may secrete beta-hCG and cause a false positive pregnancy. A pelvic US does not need to be repeated with each cycle unless the treating physician thinks it is necessary to do so.
  12. Potential subject must have the ability to understand (as judged by the treating physician) and willingness to provide written informed consent and HIPAA authorization for release of personal health information.

NOTE: HIPAA authorization may be included in the informed consent or obtained separately. Written informed consent must be obtained from a potential subject prior to the conduct of any study-specific procedures.

Exclusion Criteria

Subjects meeting any of the criteria below may not participate in the study:

  1. Patients with pure seminoma.
  2. Patients with pure teratoma.
  3. Chemotherapy within 2 weeks of initiating study treatment. There is no maximum allowable number of previous therapies.
  4. Major surgery within 3 weeks of starting study treatment. There is no minimum time requirement for minor procedures such as biopsy or vascular access placement.
  5. Radiation within 2 weeks of starting study treatment.
  6. ≥ Grade 3 neuropathy at the time of enrollment.
  7. Pregnancy or breast-feeding.
  8. Previous treatment with any anti-CD30 directed therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02689219


Locations
Layout table for location information
United States, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
United States, Indiana
Indiana University Health Hospital
Indianapolis, Indiana, United States, 46202
Indiana University Health Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States, 46202
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Costantine Albany
Investigators
Layout table for investigator information
Principal Investigator: Costantine Albany, MD Indiana University School of Medicine, Indiana University Simon Cancer Center

Layout table for additonal information
Responsible Party: Costantine Albany, Assistant Professor of Medicine, Indiana University School of Medicine
ClinicalTrials.gov Identifier: NCT02689219     History of Changes
Other Study ID Numbers: IUSCC-0568
First Posted: February 23, 2016    Key Record Dates
Last Update Posted: April 2, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Costantine Albany, Indiana University School of Medicine:
Antigens, CD30, Embryonal Germ Cell Tumors

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Neoplasms, Germ Cell and Embryonal
Carcinoma, Embryonal
Testicular Neoplasms
Neoplasms by Histologic Type
Endocrine Gland Neoplasms
Neoplasms by Site
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Endocrine System Diseases
Testicular Diseases
Gonadal Disorders
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs